Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1/2 1

Status

Unknown 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 7244Neoplasms 4539Prostatic Neoplasms 3489Colorectal Neoplasms 2940Carcinoma, Non-Small-Cell Lung 2831Lung Neoplasms 2547Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1874Multiple Myeloma 1811Carcinoma, Hepatocellular 1733Neoplasm Metastasis 1585Stomach Neoplasms 1502Lymphoma 1457Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1435Brain Neoplasms 1373Melanoma 1348Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1255Colonic Neoplasms 1204Glioblastoma 1138Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1066Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Interventional × Efficacy and Safety × Clear all
NCT04518501 2024-12-04

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Women's Hospital School Of Medicine Zhejiang University

Phase 1/2 Recruiting
50 enrolled

Efficacy and Safety

NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

NCT04284215 2020-02-25

Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC

Guizhou Medical University

Phase NA Unknown
68 enrolled

Efficacy and Safety

NCT03660761 2019-04-16

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Shandong Cancer Hospital and Institute

Phase 2 Completed
25 enrolled

Efficacy and Safety

NCT03255343 2017-08-21

ImDendrim

French Association for the Advancement Medical Research

Phase NA Unknown
10 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡